Lazcluze and Rybrevant (lazertinib and amivantamab)
pCPA File Number:
23187
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
Sponsor/Manufacturer:
Janssen Inc.
CDA-AMC Project Number:
PC0392-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable